The paclitaxel-eluting coroflex™ stent study II (PECOPS II) acute and 6-month clinical and angiographic follow-up, 1-year clinical follow-up: DRUG ELUTING STENTS

Journal of Interventional Cardiology

Volumn 23, Issue 2, 2010, Pages 160-166

  Wiemer, Marcus ^a   Degenhardt, Ralf ^b   Vallbracht, Christian ^b   Horstkotte, Dieter ^a   Schneider, Henrik ^c   Nienaber, Christoph ^c   Bocksch, Wolfgang ^d   Boxberger, Michael ^e   Unverdorben, Martin ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Center for Cardiovascular Diseases   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e B Braun Melsungen AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL;

AGED; ANGIOCARDIOGRAPHY; ARTERY LESION; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; STENT THROMBOSIS; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950562568     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2010.00529.x     Document Type: Article

References (40)

1. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003 107 : 38 42. (Pubitemid 36070930)
2. Stone G, Ellis S, Cox D, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 350 : 221 231. (Pubitemid 38067635)
3. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003 107 : 559 564. (Pubitemid 36176804)
4. ™ stent pilot study (PECOPS I): Acute and 6-month clinical and angiographic follow-up. Catheter Cardiovasc Interv 2006 67 : 703 710.
5. Unverdorben M, Degenhardt R, Sick P, et al. Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). J Invasive Cardiol 2005 17 : 199 202. (Pubitemid 40489481)
6. Unverdorben M, Degenhardt R, Wiemer M, et al. The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I): The one-year clinical follow-up. Clin Res Cardiol 2007 96 : 803 811.
7. Unverdorben M, Degenhardt R, Wiemer M, et al. The paclitaxel-eluting coroflex please stent study (PECOPS I): The 3-year clinical follow-up. Catheter Cardiovasc Interv 2009 74 : 674 682.
8. Leimgruber P, Roubin G, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986 73 : 710 717.
9. Scheller B, Cremers B, Cremers B, et al. Short and long-term effects of a novel paclitaxel coated stent in the porcine coronary artery. Clin Res Cardiol 2008 97 : 118 123.
10. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000 36 : 2325 2332.
11. Oberhoff M, Herdeg C, Al Ghobainy R, et al. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv 2001 53 : 562 568.
12. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001 103 : 2289 2295.
13. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001 104 : 473 479.
14. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents. Comparison with bare metal stents by serial intravascular ultrasound analyses: Data from the randomized TAXUS-II trial. Circulation 2004 109 : 196 200.
15. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 346 : 1773 1780.
16. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003 108 : 788 794.
17. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: The TAXi trial. J Am Coll Cardiol 2005 45 : 308 311.
18. Chen JL, Yang YJ, Qiao SB, et al. Comparison of short- and long-term outcomes between Cypher and TAXUS drug-eluting stents for in-stent restenosis. Chin Med Sci J 2007 22 : 5 8.
19. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005 95 : 113 116.
20. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 2007 369 : 1869 1875.
21. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. J Am Med Assoc 2006 295 : 895 904.
22. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005 112 : 3306 3313.
23. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004 109 : 190 195.
24. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 349 : 1315 1323.
25. Windecker S, Remondino A, Eberli FR, et al Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005 353 : 653 662. (Pubitemid 41175673)
26. Schaan BD, Quadros A, Sarmento-Leite R, et al. Diabetes and coronary stent implantation: Experience from a reference center in interventional cardiology. Arq Bras Endocrinol Metabol 2006 50 : 38 45.
27. Gao RL, Xu B, Lu SZ, et al. Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"-Clinical and angiographic results from the China CYPHER Select registry. Int J Cardiol 2008 125 : 339 346.
28. Moscoso I, Garcia LC, Dourado GO, et al. Influence of diabetes mellitus on immediate results of coronary stent: National center for cardiovascular interventions (CENIC) data analysis. Arq Bras Cardiol 2006 86 : 181 190.
29. Guagliumi G, Musumeci G. Revascularization of diabetic patients: Are drug-eluting stents the solution Ital Heart J 2005 6 : 507 513.
30. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007 369 : 667 678.
31. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007 50 : 501 508.
32. Fujiwara K, Hiasa Y, Takahashi T, et al. Influence of diabetes mellitus on outcome in the era of primary stenting for acute myocardial infarction. Circ J 2002 66 : 800 804.
33. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004 109 : 1366 1370.
34. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003 362 : 1093 1099.
35. Presbitero P, Zavalloni D, Scatturin M, et al. Procedural and long-term resutls of sirolimus-eluting stent in patients at high risk for restenosis. Minerva Cardioangiol 2004 53 : 189 194.
36. Storger H, Grube E, Hofmann M, et al. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. J Interv Cardiol 2004 17 : 387 390.
37. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Herz 2004 29 : 162 166.
38. Roy P, Okabe T, Pinto Slottow TL, et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. Am J Cardiol 2007 100 : 965 969. (Pubitemid 47368105)
39. Lee CW, Park DW, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006 97 : 506 511.
40. Cosgrave J, Agostoni P, Ge L, et al. Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 2005 96 : 1663 1668. (Pubitemid 41790388)